Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- REFINE-ICD: Efficacy of ICD Therapy in Higher Risk Post-MI Patients With Better-Preserved LV FunctionProphylactic ICD therapy did not reduce mortality in patients with a prior myocardial infarction (MI), persistent moderate left ventricular (LV) systolic dysfunction and abnormal ECG markers, according to results from the REFINE-ICD trial presented at ESC Congress 2025.
- Beta-Blocker Therapy Following MI the Focus of Late-Breaking Research at ESC Congress 2025Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025.
- VICTOR AND VICTORIA: Late-Breaking Science Explore Benefits of Vericiguat in Treating Patients With HFrEFVericiguat did not reduce the risk of a composite endpoint of time to cardiovascular death or heart failure (HF) hospitalization among patients with HF and reduced ejection fraction (HFrEF) without recent H) worsening, based on findings from the VICTOR trial...
- MAPLE-HCM: Aficamten Monotherapy vs. Metoprolol Monotherapy in Patients With Symptomatic Obstructive HCMAficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to results from the MAPLE-HCM trial...
- ODYSSEY-HCM: Mavacamten vs. Placebo in Patients With Symptomatic Nonobstructive HCMMavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), based on findings from the ODYSSEY-HCM trial...